针对21岁以下1型糖尿病患者的全国性补贴持续葡萄糖监测:2年使用率与结局的人群研究
该研究分析了全国健康政策改变后,为21岁以下1型糖尿病患者提供普遍补贴持续葡萄糖监测(CGM)的使用率及血糖结局。补贴后2年内CGM使用率从5%升至79%,12个月和24个月时HbA1c达标(<7.0%)的比值比分别为2.5和2.3(P均<0.001),24个月时HbA1c≥9.0%的比值比为0.34(P<0.001)。使用CGM超过75%时间的用户24个月HbA1c低于使用率<25%者(7.8±1.3% vs. 8.6±1.8%,P<0.001),且糖尿病酮症酸中毒发生率降低(发生率比0.49,95%CI 0.33-0.74,P<0.001)。
要点
- 补贴后2年CGM使用率由5%升至79%。
- 24个月时HbA1c<7.0%的OR为2.3(P<0.001),HbA1c≥9.0%的OR为0.34(P<0.001)。
- 使用CGM>75%时间者较<25%者24个月HbA1c更低,且糖尿病酮症酸中毒发生率比0.49(95%CI 0.33-0.74,P<0.001)。
核心结论
- 全国补贴后CGM使用率高,并与血糖控制持续改善相关;该信息将用于经济分析、未来政策制定,并作为糖尿病技术评估的模型。
研究设计与样本
- 纵向分析补贴前12个月至补贴后24个月的数据,数据来源为Australasian Diabetes Database Network(ADDN)前瞻性糖尿病数据库和国家糖尿病服务计划(NDSS)登记库(包含全国几乎所有1型糖尿病患者)。
主要发现
- CGM使用率从补贴前的5%升至2年后的79%。
- 达到HbA1c<7.0%目标的比值比在12个月时改善(OR 2.5,P<0.001),并在24个月时维持(OR 2.3,P<0.001)。
- 血糖控制欠佳(HbA1c≥9.0%)的比值比在24个月时降至0.34(P<0.001)。
- CGM用户中65%使用CGM>75%时间,其24个月HbA1c低于使用率<25%者(7.8±1.3% vs. 8.6±1.8%,P<0.001)。
- 使用CGM>75%时间组的糖尿病酮症酸中毒也减少(发生率比0.49,95%CI 0.33-0.74,P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Continuous glucose monitoring (CGM) is increasingly used in type 1 diabetes management; however, funding models vary. This study determined the uptake rate and glycemic outcomes following a change in national health policy to introduce universal subsidized CGM funding for people with type 1 diabetes aged <21 years. RESEARCH DESIGN AND METHODS: Longitudinal data from 12 months before the subsidy until 24 months after were analyzed. Measures and outcomes included age, diabetes duration, HbA1c, episodes of diabetic ketoacidosis and severe hypoglycemia, insulin regimen, CGM uptake, and percentage CGM use. Two data sources were used: the Australasian Diabetes Database Network (ADDN) registry (a prospective diabetes database) and the National Diabetes Service Scheme (NDSS) registry that includes almost all individuals with type 1 diabetes nationally. RESULTS: CGM uptake increased from 5% presubsidy to 79% after 2 years. After CGM introduction, the odds ratio (OR) of achieving the HbA1c target of <7.0% improved at 12 months (OR 2.5, P < 0.001) and was maintained at 24 months (OR 2.3, P < 0.001). The OR for suboptimal glycemic control (HbA1c ≥9.0%) decreased to 0.34 (P < 0.001) at 24 months. Of CGM users, 65% used CGM >75% of time, and had a lower HbA1c at 24 months compared with those with usage <25% (7.8 ± 1.3% vs. 8.6 ± 1.8%, respectively, P < 0.001). Diabetic ketoacidosis was also reduced in this group (incidence rate ratio 0.49, 95% CI 0.33-0.74, P < 0.001). CONCLUSIONS: Following the national subsidy, CGM use was high and associated with sustained improvement in glycemic control. This information will inform economic analyses and future policy and serve as a model of evaluation diabetes technologies.
引用
- Johnson SR, Holmes-Walker DJ, Chee M, et al. Universal Subsidized Continuous Glucose Monitoring Funding for Young People With Type 1 Diabetes: Uptake and Outcomes Over 2 Years, a Population-Based Study. Diabetes Care. 2022. PMID: 34872983. doi:10.2337/dc21-1666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。